Souhaitez-vous accéder aux communiqués récents ?

SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...

MISSISSAUGA, Ontario, 01 avr. 2026 (GLOBE NEWSWIRE) -- BioSyent inc. (« BioSyent », Bourse de croissance TSX : RX) est heureuse d’annoncer que FeraMAXMD a été désigné supplément de fer en vente...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...

Distribution agreement to enhance channel partner expansion across five U.S. states The collaboration is expected to support adoption of advanced 3D imaging within orthopedic practices and surgical...

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib...

Exclusive licensing arrangements expand RemoniHealth's Vision-as-a-Service platform; 150,000 monitoring encounters completed.

Sydney, April 01, 2026 (GLOBE NEWSWIRE) -- New global report reveals men and young adults driving soaring usage of wellness technologies  BON CHARGE™ Global Wellness Tech Trend Report...

- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care...

Foundation for Sarcoidosis Research Launches See Sarcoidosis Campaign for April's Awareness Month

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas